---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-008904"
form_type: "8-K"
ticker: "IDXX"
cik: "0000874716"
company_name: "IDEXX LABORATORIES INC /DE"
filed_at: "2026-02-02T23:59:59+00:00"
generated_at: "2026-05-16T05:50:50.281701+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IDEXX Q4 revenue $1.09B (+14% YoY), EPS $3.08 (+18%); guides FY26 rev $4.63B-$4.72B

## Summary
- Q4 revenue $1,091M (+14% as reported, +12% organic); EPS $3.08 (+18% as reported, +17% comparable).
- Full year 2025 revenue $4,304M (+10%); EPS $13.08 (+23% reported, +14% comparable).
- CAG Diagnostics recurring revenue grew 12% reported; record >1,900 IDEXX inVue Dx placements in Q4.
- FY26 guidance: rev $4,632M-$4,720M (7.6%-9.6% reported growth); EPS $14.29-$14.80 (9%-13% growth).
- Operating margin expanded 150 bps reported in Q4 to 28.9%; gross margin 60.3%, up 50 bps.

## SEC filing metadata
- accession: 0001104659-26-008904
- form_type: 8-K
- ticker: IDXX
- cik: 0000874716
- company_name: IDEXX LABORATORIES INC /DE
- filed_at: 2026-02-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874716/000110465926008904/0001104659-26-008904-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874716/000110465926008904/tm264623d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-008904
- JSON: https://secwatch.observer/filing/0001104659-26-008904.json
- Plain text: https://secwatch.observer/filing/0001104659-26-008904.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.